Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Translational challenges of remote ischemic conditioning in ischemic stroke - a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Habitual sleep disturbances and migraine: a Mendelian randomization study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The impact of gender, puberty, and pregnancy in patients with POLG disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Responsiveness of outcome measures in myotonic dystrophy type 1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Quantitative electromyography: Normative data in paraspinal muscles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Measurement of axonal excitability: Consensus guidelines

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Klinisk neurofysiologi

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskningpeer review

Vis graf over relationer

OBJECTIVE: Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by deficient activity of arylsulfatase A (ASA), resulting in severe motor and cognitive dysfunction. This phase 1/2 study evaluated the safety and efficacy of intravenous (IV) recombinant human ASA (rhASA; HGT-1111, previously known as Metazym) in children with MLD.

METHODS: Thirteen children with MLD (symptom onset < 4 years of age) were enrolled in an open-label, nonrandomized, dose-escalation trial and received IV rhASA at 50, 100, or 200 U/kg body weight every 14 (± 4) days for 52 weeks (NCT00418561; NCT00633139). Eleven children continued to receive rhASA at 100 or 200 U/kg during a 24-month extension period (NCT00681811). Outcome measures included safety observations, changes in motor and cognitive function, and changes in nerve conduction and morphometry.

RESULTS: There were no serious adverse events considered related to IV rhASA. Motor function and developmental testing scores declined during the study in all dose groups; no significant differences were observed between groups. Nerve conduction studies and morphometric analysis indicated that peripheral nerve pathology did not worsen during the study in any dose group.

INTERPRETATION: IV rhASA was generally well tolerated. There was no evidence of efficacy in preventing motor and cognitive deterioration, suggesting that IV rhASA may not cross the blood-brain barrier in therapeutic quantities. The relative stability of peripheral nerve function during the study indicates that rhASA may be beneficial if delivered to the appropriate target site and supports the development of rhASA for intrathecal administration in MLD.

OriginalsprogEngelsk
TidsskriftAnnals of Clinical and Translational Neurology
Vol/bind8
Udgave nummer1
Sider (fra-til)66-80
Antal sider15
ISSN2328-9503
DOI
StatusUdgivet - jan. 2021

Bibliografisk note

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

ID: 62083229